Fructose metabolism and metabolic disease.
Hannou SA, Haslam DE, McKeown NM, Herman MA.
J Clin Invest. 2018 Feb 1;128(2):545-555. doi: 10.1172/JCI96702. Epub 2018 Feb 1.
Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.
Jensen T, Abdelmalek MF, Sullivan S, Nadeau KJ, Green M, Roncal C, Nakagawa T, Kuwabara M, Sato Y, Kang DH, Tolan DR, Sanchez-Lozada LG, Rosen HR, Lanaspa MA, Diehl AM, Johnson RJ.
J Hepatol. 2018 May;68(5):1063-1075. doi: 10.1016/j.jhep.2018.01.019. Epub 2018 Feb 2.
Dietary Fructose and Fructose-Induced Pathologies.
Jung S, Bae H, Song WS, Jang C.
Annu Rev Nutr. 2022 Aug 22;42:45-66. doi: 10.1146/annurev-nutr-062220-025831.
Pathogenesis of Hypertension in Metabolic Syndrome: The Role of Fructose and Salt.
Soleimani M, Barone S, Luo H, Zahedi K.
Int J Mol Sci. 2023 Feb 21;24(5):4294. doi: 10.3390/ijms24054294.
Fructose and hepatic insulin resistance.
Softic S, Stanhope KL, Boucher J, Divanovic S, Lanaspa MA, Johnson RJ, Kahn CR.
Crit Rev Clin Lab Sci. 2020 Aug;57(5):308-322. doi: 10.1080/10408363.2019.1711360. Epub 2020 Jan 14.
Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease.
Softic S, Cohen DE, Kahn CR.
Dig Dis Sci. 2016 May;61(5):1282-93. doi: 10.1007/s10620-016-4054-0. Epub 2016 Feb 8.
Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate.
Zhao S, Jang C, Liu J, Uehara K, Gilbert M, Izzo L, Zeng X, Trefely S, Fernandez S, Carrer A, Miller KD, Schug ZT, Snyder NW, Gade TP, Titchenell PM, Rabinowitz JD, Wellen KE.
Nature. 2020 Mar;579(7800):586-591. doi: 10.1038/s41586-020-2101-7. Epub 2020 Mar 18.
The fructose survival hypothesis for obesity.
Johnson RJ, Lanaspa MA, Sanchez-Lozada LG, Tolan D, Nakagawa T, Ishimoto T, Andres-Hernando A, Rodriguez-Iturbe B, Stenvinkel P.
Philos Trans R Soc Lond B Biol Sci. 2023 Sep 11;378(1885):20220230. doi: 10.1098/rstb.2022.0230. Epub 2023 Jul 24.
"Sweet death": Fructose as a metabolic toxin that targets the gut-liver axis.
Febbraio MA, Karin M.
Cell Metab. 2021 Dec 7;33(12):2316-2328. doi: 10.1016/j.cmet.2021.09.004. Epub 2021 Oct 6.
Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota.
Drożdż K, Nabrdalik K, Hajzler W, Kwiendacz H, Gumprecht J, Lip GYH.
Nutrients. 2021 Dec 27;14(1):103. doi: 10.3390/nu14010103.
